Coverage & Payment / Government & Legislative Affairs / Regulatory Affairs

AdvaMed Congratulates Dr. Oz on his Confirmation as CMS Administrator 

Washington, D.C.– AdvaMed®, the Medtech Association, today released the following statement from President and CEO Scott Whitaker on the U.S. Senate’s confirmation of Dr. Mehmet Oz to serve as Administrator of…

Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Small Business

AdvaMed®’s Medical Innovation Agenda for the 119th Congress

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

Online

Richardson Waiver Repeal: What it Means for Medtech

Sidley Austin, joined by HPA, will lead a program examining the impact of HHS repealing the so-called “Richardson Waiver”, including its history, how it could impact the activities of the…

Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Health Equity / Legal / Regulatory Affairs / Small Business

The Medical Innovation Agenda for the 119th Congress

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

A document titled "The Impact of Tariffs on Patient Access to Medical Technology" features sections discussing the importance of the medtech industry and the negative effects of import tariffs on healthcare costs, supply chains, and patient access. The document is formatted with bullet points and bolded key terms
Coverage & Payment / Emerging Policy Response Resources / Global & Trade / Supply Chain / Tariffs

The Impact of Tariffs on Patient Access to Medical Technology

Tariffs on medtech could disrupt supply chains, increase costs, and delay care. Exemptions are needed to protect hospitals, patients, and innovation.

In Person

AdvaMed® Payment Policy Forum

Gain insights from thought leaders and industry experts as they delve into medtech payment policies, private payer challenges and more.